Lv45
454 积分 2023-08-23 加入
The regulation and differentiation of regulatory T cells and their dysfunction in autoimmune diseases
1天前
已完结
The race to reset autoimmune diseases
1天前
已完结
TargetPair: A Single Cell-omics Resource of Clinical Trials-derived Therapeutical Target Combinations for Cancer Therapy
2天前
求助中
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
2天前
已完结
Trends in the drug target landscape for autoimmune diseases
3天前
已完结
Sequential immunotherapy: towards cures for autoimmunity
3天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
7天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
8天前
已完结
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study
8天前
已完结
Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC
8天前
已完结
皖公网安备34019202002308
